Music therapy reduces distress and improves well-being in advanced dementia by meeting unmet needs, enhancing ...
Huahui Health, a clinical-stage biotechnology company focused on discovering and developing novel therapies in the areas of viral hepatitis, hepatology, and oncology, today announced that its ...
2don MSN
A clinical trial has shown promising results in treating brain tumours in children using an immune-cell therapy known as ...
Nipocalimab is a fully human monoclonal antibody that blocks FcRn and decreases levels of circulating IgG antibodies.
GlobalData on MSN7d
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatmentThe US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & ...
MyChesCo on MSN1d
FDA Grants Breakthrough Therapy Designation to Johnson & Johnson’s Nipocalimab for Sjögren’s DiseaseJohnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation ...
Johnson & Johnson announced that the U.S. Food and Drug Administration has granted nipocalimab Breakthrough Therapy designation for the ...
Research from the College of Medicine provides promising insights into delaying the progression of Alzheimer’s disease for several years after the initial diagnosis. A recent study by researchers at C ...
Johnson & Johnson said its nipocalimab treatment for adults living with moderate-to-severe Sjögren's disease has received breakthrough therapy designation from the Food and Drug Administration.
Johnson & Johnson (J&J) has announced that its anti-FcRn antibody nipocalimab has become the first investigational therapy to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback